secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001193125-25-315039
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus posts Phase 1a data for CRB-913: weight loss signal, no serious AEs; Phase 1b started
--------------------------------------------------------------------------------

- Phase 1a SAD/MAD of oral CB1 inverse agonist CRB-913 (n=112) showed no serious AEs, no GI intolerability, no neuropsychiatric events except mild anxiety/irritability in obese cohort.
- In obese MAD cohort (150 mg QD), all 9 CRB-913-treated participants lost weight; mean placebo-adjusted 2.9% loss at Day 14 (range 1.3-4.3%).
- Initiated Phase 1b CANYON-1 (12-week, 240 obese non-diabetic participants, doses 20/40/60 mg); completion expected summer 2026.
- PK profile supports once-daily dosing; no suicidality, depression, or insomnia reported across all study cohorts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000119312525315039/0001193125-25-315039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000119312525315039/crbp-20251211.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-315039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer